What Is Semaglutide, and Why Is It Everywhere?

A hormone your gut already makes

Semaglutide is not a strange lab intruder. Think of it as a long-lasting stand-in for GLP-1, a hormone your own gut releases after a meal. That hormone does two jobs. It tells the pancreas to release insulin, but only when your blood sugar is actually high, and it tells your brain you are full. The problem with natural GLP-1 is that it evaporates. The body clears it in a couple of minutes, which makes the real hormone useless as a medicine.

Semaglutide fixes that with one small design change. The molecule is shaped so the body breaks it down much more slowly, which is how a single shot can last a week. The result shows up in two ways people notice. Blood sugar drifts down, and weight follows, partly because people simply want less food. Users often describe a quieter change too: the constant background hum of wanting something to eat goes still.

None of this happened by accident. Novo Nordisk spent years tweaking the molecule so one injection would last a week. The appetite effect that turned semaglutide into a weight-loss phenomenon was, by several accounts, partly a surprise. Researchers expected better blood sugar. The quieter hunger, and the weight loss that followed, made it a different kind of drug.

Ozempic, Wegovy, Rybelsus: one molecule, three jobs

The three names confuse people because they are one molecule wearing different labels. Ozempic is approved for type 2 diabetes. Wegovy is a higher dose approved for weight management. Rybelsus is the oral form. Same active ingredient, different doses, different official purposes. That is why one name keeps showing up attached to stories that look unrelated.

The lizard that started it

Before semaglutide, there was a reptile. In 1992, John Eng, a researcher at the James J. Peters VA Medical Center in the Bronx, isolated a peptide from Gila monster venom and named it exendin-4. It behaved like human GLP-1 but lasted hours instead of minutes. That discovery, made with veterans funding in a Nobel laureate's laboratory, became the first GLP-1 drug, exenatide, approved in 2005. Everything after it descends from that one lizard.

Why the searches spiked this week

The name is in the news for several reasons at once, which is exactly why one search term carries so many people. On August 18, two large Ontario public-sector unions asked the provincial government to widen drug coverage so semaglutide medicines are paid for whenever a doctor prescribes them, not only for type 2 diabetes, and to cover cheaper generic versions. On August 17, Brazil's health regulator approved two new generic semaglutide pens. On August 19, Novo Nordisk confirmed it has started a trial to find the lowest dose of its oral Wegovy pill that still works.

Underneath those headlines sits a quieter one that matters more to your wallet. Novo Nordisk has said it will cut the U.S. list price of Wegovy and Ozempic to $675 a month starting January 1, 2027. That is roughly half off Wegovy and about a third off Ozempic, and it is aimed at people whose bills track the list price, such as those on high-deductible plans.

What happens next

Expect the medicine to keep spreading in three directions.

• Cheaper versions. Generics are arriving in Brazil and elsewhere, and the U.S. price cut lands on January 1, 2027.
• More uses. Researchers are testing semaglutide far beyond diabetes, including whether it might protect the brain against dementia.
• More people. One in eight U.S. adults already takes a GLP-1 drug, and that share keeps climbing.

Take the brain research as one example. An analysis of roughly one million people with type 2 diabetes found semaglutide was tied to a 40 to 70 percent lower chance of a first Alzheimer's diagnosis compared with other diabetes drugs. That sounds like a miracle, and it is not one. A large clinical trial testing oral semaglutide against Alzheimer's failed to slow the disease. The gap between those two results is where the honest uncertainty lives, and it is a reminder that association is not proof.

Strip away the brand names and the news cycle, and semaglutide is a simple idea. At its core, semaglutide is a copy of a hormone you already make, stretched so it lasts longer. Its career is nowhere near finished, and it all started with a lizard that barely needs to eat.